| INTRODUCTION
The incidence of non-Hodgkin lymphoma (NHL) in humans has long been known to be variable based on region. The more developed regions tend to have the highest incidence of NHL including North America, Western Europe and Australia. 1, 2 Some areas of Africa with a high incidence of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome also have a high incidence of NHL. 2 Trends in survival differences can also be seen by geographical regions for various tumour types including NHL. In 1 study, evaluating 5-year NHL survival percentages for 10 European Countries and a total of 11 diverse areas of Europe, Cracow and Estonia had the lowest 5-year survival rates at 36.4% and 38.8%, respectively, whereas Geneva and Saarland had the highest 5-year survival rates at 61.9% and 60.6%, respectively, in the same year. 3 Differences in treatment outcomes based on geography for various other tumour types have been reported in the human literature.
One study evaluating the clinical presentation and severity of intravascular lymphoma (IVL) in Eastern and Western populations determined that 44% of Japanese patients had hemophagocytosis associated with their IVL, while none of the Western patients had hemophagocytosis. 4 A study evaluating the treatment outcomes of patients with colorectal cancer demonstrated a decrease in overall survival in northern Manitoba compared with other areas of the province. 5 Another study evaluating the level of care of patients with rectal cancer in the United States found that geography played a role in the dose and schedule of adjuvant of neoadjuvant therapy a patient received. This in turn affected survival. The number of cases that each treatment centre evaluated per year also influenced the rate of adjuvant and neoadjuvant therapies instituted. 6 Another study evaluating prostate cancer survival in New South Wales determined that men living in rural areas and socio-economically disadvantaged areas were significantly more likely to die of prostate cancer than those in urban and wealthy areas. 7 These differences may represent differences in availability of advanced medical care, rate of early detection and diagnosis, rate of commonly used screening tests, socioeconomic factors and differences in tumour subtype distributions among other causes. 3, 5, 7 Lymphoma is one of the most common malignancies diagnosed in pet dogs in the United States. [8] [9] [10] Lymphoma represents a diverse group of diseases similar to those seen in humans, with those of the non-Hodgkin B-cell phenotype being most commonly diagnosed. 8 The aetiology of lymphoma in companion animals is generally unknown and likely multifactorial; however, a genetic predisposition with certain breed associations certainly exists. 8, 9 In addition, there is evidence that environmental factors such as exposure to herbicides and other chemicals may modify breedassociated risk. A multivariable Cox regression model was built to assess the association or effect of the potential predictor variables. Those variables with a P-value of .25 or less on univariate analysis were initially put into the multivariable model. Predictors were manually dropped from the model using a backward elimination process based on individual variable P-values. All possible 2-way interactions between these variables were assessed. Collinearity was not specifically evaluated, but was biologically considered unlikely. The assumption of proportionality was confirmed by including time-dependent covariates in the model. Model fit was evaluated using Cox-Snell residuals. Analyses were performed using STATA software, Intercooled version 12.0. Statistical significance was assessed at P < .05.
| RESULTS
In total, 803 abstracted records were received and a total 775 dogs included in the analysis. Reasons for case exclusion included an intent to treat with CHOP chemotherapy but doxorubicin was never administered (1 case) and unconfirmed cytologic diagnoses (27 cases).
Breeds represented included mixed breed (n = 161, 20.7%), golden retriever (n = 97, 12.5%), Labrador retriever (n = 57, 7.3%), boxer (n = 28, 3.6%), German shepherd (n = 28, 3.6%), rottweiler (n = 25, 3.2%), beagle (n = 22, 2.8%), border collie (n = 24, 3.1%), basset hound (n = 17, 2.2%), miniature schnauzer (n = 17, 2.2%), cocker spaniel (n = 15, 1.9%), Jack Russell terrier (n = 12, 1.5%), Shetland sheepdog (n = 12, 1.5%), shih tzu (n = 12, 1.5%), American Staffordshire terrier (n = 11, 1.4%), Australian shepherd (n = 10, 1.3%), doberman pinscher (n = 10, 1.3%), English bulldog (n = 10, 1.3%), Scottish terrier (n = 10, 1.3%), Welsh corgi (n = 10, 1.3%) and other breeds with less than 10 representatives (n = 193, 24.9%). A total of 81 dogs were included from the western region, 401 dogs were included from the southern region, and 293 dogs were included from the northern region. Study dogs comprised of 354 (45.7%) neutered males, 302 (38.9%) spayed females, 75 (9.7%) intact males and 44 (5.7%) intact females, with a median age at diagnosis of 8.0 years (range:
1.7-18.3 years). Of the 775 cases included in the study, 176 (22.7%) cases had a histopathologic diagnosis of lymphoma, 428 cases had a cytologic diagnosis of lymphoma (55.2%) and the method of diagnosis was not reported for 171 cases (22.1%).
Sex (P = .05), weight (P = .049), stage (P < .001), immunophenotype (P = <.001) and number of doxorubicin doses (P = .001) differed by region (Table 1) All included dogs experienced recurrence or progressive disease, with date of death also available for 598 dogs. The median PFS for all dogs enrolled was 204 days (interquartile range: 89-322 days). Upon univariate analysis, PFS differed significantly between geographic regions (P = .006), stage (P = .0094), sub-stage (P < .001) and immunophenotype (P < .001) ( Table 2 , Figures 1-4) . There was no difference in PFS by sex (P = .921), weight (P = .504) or age (P = .121).
Region, stage, sub-stage and immunophenotype were included in the final model (Table 3 ). The proportional hazards assumption was met.
No interaction terms were significant. Dogs in the western region had a significantly shorter PFS when compared with the south (Hazard ratio, HR = 0.722) and east (HR = 0.623). Survival was also significantly affected by stage, sub-stage and phenotype (Table 3 ). As in human studies, socio-economic differences may play a role in survival outcomes for our canine patients as well. Based on data from the US Census Bureau, the median household income by state was lowest in the South Eastern areas of the country with the 8 of Chronic antigenic stimulation has been associated with increased risk of NHL development in humans, especially in older individuals. 27 One study found that respiratory and skin infections in humans were linked with an increased risk of NHL, whereas gastrointestinal and urinary tract infections were not. 28 Another study of 33 patients with rheumatoid arthritis demonstrated a shortened survival with lymphoma suggesting a more aggressive behaviour in cases with chronic inflammation. 29 These patients were also more likely to develop diffuse large B-cell lymphoma, which carries a poorer prognosis other NHL subtypes. 29, 30 In veterinary medicine a study by Keller et al 31 reported an increased risk of developing lymphoma in dogs with immune-mediated thrombocytopenia. Southern states are known for harbouring more infectious diseases because of a warmer climate, larger feral animal population and increased numbers of vectors (because of habitat requirements). A case report of an 11-year-old dog with concurrent T-cell lymphoma and Heterobilharzia suggested that, as in humans, schistosomiasis might contribute to the development of lymphoma. This aggressive lymphoma was refractory to treatment and the disease progressed rapidly. 32 There is also an increase in the incidence of atopic conditions among pet populations in the South, again because of the warmer climates. In humans, B-cell lymphomas are thought to occasionally occur in individuals with chronic antigenic stimulation. 27 The cellular signals from other cells in the inflammatory environment provide survival and proliferation signals that may lead to malignant transformation or sustained tumour cell growth. 33, 34 Though these causes more often are described in terms of incidence, they may also play a role in the biologic activity of the tumours they cause. HIV associated lymphomas (HAL) are known to have a very aggressive clinical behaviour compared with similar non-HIV related NHLs. This is thought to be related to an increased proliferation rate and a decrease in DNA aneuploidy in the HAL cases suggesting a difference in tumour pathogenesis. 35 The same phenomenon is seen in cats with a positive retroviral status that develop lymphoid malignancies. 36, 37 It is beyond the scope of this study to evaluate these cases for possible co-morbidities at this time.
| DISCUSSION
Future studies will be needed to determine antigenic stimulation plays a role geographically in canine lymphoma.
In a review of the current literature, the regional PFS differences reported in this study appear to be consistent with other published reports. The median PFS for all animals in this study falls short of the 282 days reported by Garrett et al, 14 Abbreviations: HR, hazard ratio; CI, confidence interval.
1 HR is presented for each sub-category (presented first) vs the baseline category (presented second). (Table 4 ).
In another recently published paper by Ruple et al, 41 a difference in the geographic distribution of lymphoma subtypes in Golden retrievers was noted. In this study, dogs in the Northeast and East North
Central regions were more likely to be diagnosed with T-zone lymphoma than B-cell lymphoma. Given the indolent nature of T-zone lymphoma in dogs, it would stand to reason that these dogs would likely live longer than some of other subtypes of lymphoma diagnosed in the dog. T-zone lymphoma cases were not included in this study, which focused on intermediate or high grade lymphomas treated with the CHOP protocol. However, this study does support the idea that geographic differences in canine lymphoma may exist and may be environmentally driven.
Limitations to the study include its retrospective nature, lack of standardized criteria or requirement for full staging, lack of histologic diagnoses contributing to NHL subtype, inclusion of only a referral population of dogs and inherent difficulties with chemotherapy protocols. It is unknown if a referral population of dogs with lymphoma is truly representative of the disease in these regions. Despite these limitations, the purpose of the study was simply to identify if geographic differences in NHL do exist across the United States.
Indeed, preliminary results here support our hypothesis that there are geographic differences amongst dogs with NHL, although it is still unclear how multifactorial these differences are and how much influence prognostic factors may have on outcome. Further studies should strive to prospectively evaluate geographic differences through strict standardized means in order to better elucidate underlying mechanisms contributing to differences.
In conclusion, these data suggest that there may indeed be geographical differences in the PFS of dogs with lymphoma for reasons other than the traditionally considered negative prognostic factors. The authors of this article were unable to determine a cause for the differences in PFS between regions. Limitations of this study include the retrospective nature of the study, the collection of cases from referral hospitals only, the relatively small number of hospitals per region which submitted cases and the relatively low number of dogs considered given the estimated canine populations in those areas. These limitations certainly allow for the possibility of alternative explanations for this data. Regretfully, too few of the patients included in this study have histopathology confirming the specific type of lymphoma to investigate this further. Future studies will be needed to determine the underlying cause of these differences. 
